Ruan Zegang, Zhuo Xin, Xu Chenyang
Department of Thoracic Surgery, Ganzhou People's Hospital, Jiangxi Medical College, Nanchang University, Ganzhou, Jiangxi, China.
Front Oncol. 2024 Jan 15;13:1310471. doi: 10.3389/fonc.2023.1310471. eCollection 2023.
With the increasing implementation of early lung cancer screening and the increasing emphasis on physical examinations, the early-stage lung cancer detection rate continues to rise. Visceral pleural invasion (VPI), which denotes the tumor's breach of the elastic layer or reaching the surface of the visceral pleura, stands as a pivotal factor that impacts the prognosis of patients with non-small cell lung cancer (NSCLC) and directly influences the pathological staging of early-stage cases. According to the latest 9th edition of the TNM staging system for NSCLC, even when the tumor diameter is less than 3 cm, the final T stage remains T2a if VPI is present. There is considerable controversy within the guidelines regarding treatment options for stage IB NSCLC, especially among patients exhibiting VPI. Moreover, the precise determination of VPI is important in guiding treatment selection and prognostic evaluation in individuals with NSCLC. This article aims to provide a comprehensive review of the current status and advancements in studies pertaining to stage IB NSCLC accompanied by VPI.
随着早期肺癌筛查的日益普及以及对体检的日益重视，早期肺癌的检出率持续上升。脏层胸膜侵犯（VPI），即肿瘤突破弹性层或到达脏层胸膜表面，是影响非小细胞肺癌（NSCLC）患者预后的关键因素，并直接影响早期病例的病理分期。根据最新的第9版NSCLC的TNM分期系统，即使肿瘤直径小于3 cm，但如果存在VPI，最终T分期仍为T2a。在指南中，对于IB期NSCLC的治疗方案存在相当大的争议，尤其是在表现出VPI的患者中。此外，准确确定VPI对于指导NSCLC患者的治疗选择和预后评估至关重要。本文旨在全面综述伴有VPI 的IB期NSCLC的研究现状和进展。
